Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19 - 18/10/22
, Thomas C.S. Martin a, b
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
The return of COVID-19 symptoms after Nirmatrelvir/Ritonavir (Nm/R) treatment is being increasingly reported. Limited evidence suggests most cases of rebound symptoms are mild and do not require further intervention. Here we present a male veteran reporting rebound symptoms who was found to be hypoxic with pulmonary emboli. Our case highlights the need to evaluate known complications of SARS-CoV-2 including venous thromboembolism in patients reporting recurring symptoms. Further, cases of severe rebound phenomenon should continue to be reported by clinicians to better appreciate the use of the Nm/R during the Omicron wave and among vaccinated persons.
Le texte complet de cet article est disponible en PDF.Keywords : SARS-CoV-2, Paxlovid, Paxlovid rebound, COVID-19: Pulmonary embolism
Plan
Vol 61
P. 235.e5-235.e6 - novembre 2022 Retour au numéro
Article précédent
- The imperfect storm: An uncommon presentation of Chagas disease
- Matthew C. Johnson, Lulu Wang
- Mycobacterium marinum cellulitis: A fishy etiology
- Rachel E. Bridwell, Cody F. Newell, Brannon L. Inman, Sarah Goss, Brit Long
Bienvenue sur EM-consulte, la référence des professionnels de santé.